Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EMD 1201081 + cetuximab
- Development stage
- Phase 2
- Lead developer
- EMD Serono
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
EMD 1201081 + cetuximab is a combination of an immunomodulatory oligonucleotide (EMD 1201081) and a monoclonal antibody (cetuximab) investigated for the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). EMD 1201081 is a synthetic phosphorothioate oligodeoxynucleotide that acts as an agonist of Toll-like receptor 9 (TLR9), leading to immune system activation. Cetuximab is a chimeric monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), thus blocking cell proliferation signals in cancer cells. The combination was evaluated in phase 2 clinical trials to determine if it offers increased antitumor activity compared to cetuximab monotherapy; while well tolerated, the combination did not demonstrate increased efficacy over cetuximab alone[1][2][4][5].
02
Targets
EGFR (Epidermal growth factor receptor)TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on EMD 1201081 + cetuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EMD 1201081 + cetuximab.